Self-transfers and factors associated with successful tracing among persons lost to follow-up from HIV care, Sheema District, Southwestern Uganda: retrospective medical records review, 2017-2021.
Antiretroviral therapy
HIV
Loss to follow-up
Self-transfer
Tracing
Uganda
Journal
AIDS research and therapy
ISSN: 1742-6405
Titre abrégé: AIDS Res Ther
Pays: England
ID NLM: 101237921
Informations de publication
Date de publication:
20 09 2022
20 09 2022
Historique:
received:
25
05
2022
accepted:
12
09
2022
entrez:
20
9
2022
pubmed:
21
9
2022
medline:
24
9
2022
Statut:
epublish
Résumé
Due to improved coverage and scale-up of antiretroviral therapy (ART), patients are increasingly transferring between ART-providing sites. Self-transfers may constitute a high proportion of patients considered lost to follow-up (LTFU), and if overlooked when reporting patients who have dropped out of HIV care, may result in an incorrect estimation of retention. We determined the prevalence of self-transfers, and successful tracing, and identified associated factors among people living with HIV (PLHIV) LTFU from care at public health facilities in Sheema District, Southwestern Uganda. We conducted a cross-sectional retrospective medical records review during February and March 2022. We included records of all PLHIV who were LTFU from 2017 to 2021, and who were registered at government-owned ART clinics in Sheema District. LTFU was considered for those who were not taking ART refills for a period of ≥ 3 months. We abstracted demographic and clinical data from medical records at the selected clinics. Participants were traced via phone calls or in-person to ascertain the outcomes of LTFU. We performed multivariate modified Poisson regression to identify factors associated with self-transfer, and successful tracing. Overall, 740 patients were identified as LTFU from three ART-providing clinics; of these, 560 (76%) were self-transfers. The mean age was 30 (SD ± 10) years, and most (69%, n = 514) were female; the majority (87%, 641/740) were successfully traced. Age (adjusted prevalence ratio [aPR] = 1.13, 95% CI 1.01-1.25, P = 0.026 for those aged 18-30 years compared to > 30 years), female sex (aPR = 1.18, 95% CI 1.11-1.25, P < 0.001), and having WHO clinical stage 1-2 (aPR = 2.34, 95% CI 1.89-3.91, P < 0.001) were significantly associated with self-transfer. Presence of a phone contact in the patient's file (aPR = 1.10, 95% CI 1.01-1.90, P = 0.026) was associated with successful tracing of the patients considered LTFU. Self-transfers accounted for the majority of patients recorded as LTFU, highlighting the need to account for self-transfers among patients considered LTFU, to accurately estimate retention in care. ART-providing facilities should regularly update contact information for PLHIV to enable successful tracing, in the event that the patients are LTFU. This calls for a health-tracking system that easily identifies self-transfers across ART-providing clinics using unique patient identifiers.
Sections du résumé
BACKGROUND
Due to improved coverage and scale-up of antiretroviral therapy (ART), patients are increasingly transferring between ART-providing sites. Self-transfers may constitute a high proportion of patients considered lost to follow-up (LTFU), and if overlooked when reporting patients who have dropped out of HIV care, may result in an incorrect estimation of retention. We determined the prevalence of self-transfers, and successful tracing, and identified associated factors among people living with HIV (PLHIV) LTFU from care at public health facilities in Sheema District, Southwestern Uganda.
METHODS
We conducted a cross-sectional retrospective medical records review during February and March 2022. We included records of all PLHIV who were LTFU from 2017 to 2021, and who were registered at government-owned ART clinics in Sheema District. LTFU was considered for those who were not taking ART refills for a period of ≥ 3 months. We abstracted demographic and clinical data from medical records at the selected clinics. Participants were traced via phone calls or in-person to ascertain the outcomes of LTFU. We performed multivariate modified Poisson regression to identify factors associated with self-transfer, and successful tracing.
RESULTS
Overall, 740 patients were identified as LTFU from three ART-providing clinics; of these, 560 (76%) were self-transfers. The mean age was 30 (SD ± 10) years, and most (69%, n = 514) were female; the majority (87%, 641/740) were successfully traced. Age (adjusted prevalence ratio [aPR] = 1.13, 95% CI 1.01-1.25, P = 0.026 for those aged 18-30 years compared to > 30 years), female sex (aPR = 1.18, 95% CI 1.11-1.25, P < 0.001), and having WHO clinical stage 1-2 (aPR = 2.34, 95% CI 1.89-3.91, P < 0.001) were significantly associated with self-transfer. Presence of a phone contact in the patient's file (aPR = 1.10, 95% CI 1.01-1.90, P = 0.026) was associated with successful tracing of the patients considered LTFU.
CONCLUSION
Self-transfers accounted for the majority of patients recorded as LTFU, highlighting the need to account for self-transfers among patients considered LTFU, to accurately estimate retention in care. ART-providing facilities should regularly update contact information for PLHIV to enable successful tracing, in the event that the patients are LTFU. This calls for a health-tracking system that easily identifies self-transfers across ART-providing clinics using unique patient identifiers.
Identifiants
pubmed: 36127692
doi: 10.1186/s12981-022-00471-2
pii: 10.1186/s12981-022-00471-2
pmc: PMC9487036
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
44Subventions
Organisme : FIC NIH HHS
ID : R25 TW011210
Pays : United States
Informations de copyright
© 2022. The Author(s).
Références
BMJ Open. 2018 Apr 20;8(4):e017487
pubmed: 29678963
J Int AIDS Soc. 2014 Aug 01;17:19032
pubmed: 25095831
S Afr Med J. 2007 Sep;97(9):853-7
pubmed: 17985056
PLoS One. 2009 Jun 04;4(6):e5790
pubmed: 19495419
J Int AIDS Soc. 2016 Dec 01;19(1):21484
pubmed: 27914186
J Acquir Immune Defic Syndr. 2012 Apr 1;59(4):e52-9
pubmed: 22217680
J Acquir Immune Defic Syndr. 2017 Sep 1;76(1):e15-e18
pubmed: 28394821
PLoS Med. 2017 Apr 11;14(4):e1002268
pubmed: 28399160
BMC Med Res Methodol. 2003 Oct 20;3:21
pubmed: 14567763
Trop Med Int Health. 2015 Mar;20(3):365-79
pubmed: 25418366
PLoS One. 2020 Apr 7;15(4):e0217606
pubmed: 32255796
Trop Med Int Health. 2010 Jun;15 Suppl 1:1-15
pubmed: 20586956
BMC Infect Dis. 2011 Jan 27;11:31
pubmed: 21272350
J Int Assoc Provid AIDS Care. 2015 Nov-Dec;14 Suppl 1:S3-S34
pubmed: 26527218
Trop Med Health. 2019 Nov 06;47:52
pubmed: 31719791
Trop Med Int Health. 2010 Jun;15 Suppl 1:63-9
pubmed: 20586962
AIDS. 2012 Oct 23;26(16):2059-67
pubmed: 22781227
Implement Sci. 2017 Apr 4;12(1):45
pubmed: 28376834
PLoS One. 2013;8(3):e57907
pubmed: 23472118
J Acquir Immune Defic Syndr. 2008 Jan 1;47(1):101-7
pubmed: 17971708